{
    "title": "Orphan Products Extension Now Accelerating Cures and Treatments Act of 2017",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Orphan Products Extension Now \nAccelerating Cures and Treatments Act of 2017''.\n\nSEC. 2. EXTENSION OF EXCLUSIVITY PERIODS FOR A DRUG APPROVED FOR A NEW \n              INDICATION FOR A RARE DISEASE OR CONDITION.\n\n    (a) In General.--The Federal Food, Drug, and Cosmetic Act is \namended by inserting after section 505F of such Act (21 U.S.C. 355g) \nthe following:\n\n``SEC. 505G. EXTENSION OF EXCLUSIVITY PERIODS FOR A DRUG APPROVED FOR A \n              NEW INDICATION FOR A RARE DISEASE OR CONDITION.\n\n    ``(a) Designation.--\n            ``(1) In general.--The Secretary shall designate a drug as \n        a drug approved for a new indication to prevent, diagnose, or \n        treat a rare disease or condition for purposes of granting the \n        extensions under subsection (b) if--\n                    ``(A) prior to approval of an application or \n                supplemental application for the new indication, the \n                drug was approved or licensed under section 505(c) of \n                this Act or section 351(a) of the Public Health Service \n                Act but was not so approved or licensed for the new \n                indication;\n                    ``(B)(i) the sponsor of the approved or licensed \n                drug files an application or a supplemental application \n                for approval of the new indication for use of the drug \n                to prevent, diagnose, or treat the rare disease or \n                condition; and\n                    ``(ii) the Secretary approves the application or \n                supplemental application; and\n                    ``(C) the application or supplemental application \n                for the new indication contains the consent of the \n                applicant to public notice under paragraph (3) with \n                respect to the designation of the drug.\n            ``(2) Revocation of designation.--\n                    ``(A) In general.--Except as provided in \n                subparagraph (B), a designation under paragraph (1) \n                shall not be revoked for any reason.\n                    ``(B) Exception.--The Secretary may revoke a \n                designation of a drug under paragraph (1) if the \n                Secretary finds that the application or supplemental \n                application resulting in such designation contained an \n                untrue statement of material fact.\n            ``(3) Notice to public.--The Secretary shall provide public \n        notice of the designation of a drug under paragraph (1).\n    ``(b) Extension.--\n            ``(1) In general.--If the Secretary designates a drug as a \n        drug approved for a new indication for a rare disease or \n        condition, as described in subsection (a)(1)--\n                    ``(A)(i) the 4-, 5-, and 7\\1/2\\-year periods \n                described in subsections (c)(3)(E)(ii) and \n                (j)(5)(F)(ii) of section 505, the 3-year periods \n                described in clauses (iii) and (iv) of subsection \n                (c)(3)(E) and clauses (iii) and (iv) of subsection \n                (j)(5)(F) of section 505, and the 7-year period \n                described in section 527, as applicable, shall be \n                extended by 6 months; or\n                    ``(ii) the 4- and 12-year periods described in \n                subparagraphs (A) and (B) of section 351(k)(7) of the \n                Public Health Service Act and the 7-year period \n                described in section 527, as applicable, shall be \n                extended by 6 months; and\n                    ``(B)(i) if the drug is the subject of a listed \n                patent for which a certification has been submitted \n                under subsection (b)(2)(A)(ii) or (j)(2)(A)(vii)(II) of \n                section 505 or a listed patent for which a \n                certification has been submitted under subsection \n                (b)(2)(A)(iii) or (j)(2)(A)(vii)(III) of section 505, \n                the period during which an application may not be \n                approved under section 505(c)(3) or section \n                505(j)(5)(B) shall be extended by a period of 6 months \n                after the date the patent expires (including any patent \n                extensions); or\n                    ``(ii) if the drug is the subject of a listed \n                patent for which a certification has been submitted \n                under subsection (b)(2)(A)(iv) or (j)(2)(A)(vii)(IV) of \n                section 505, and in the patent infringement litigation \n                resulting from the certification the court determines \n                that the patent is valid and would be infringed, the \n                period during which an application may not be approved \n                under section 505(c)(3) or section 505(j)(5)(B) shall \n                be extended by a period of 6 months after the date the \n                patent expires (including any patent extensions).\n            ``(2) Relation to pediatric and qualified infectious \n        disease product exclusivity.--Any extension under paragraph (1) \n        of a period shall be in addition to any extension of the \n        periods under sections 505A and 505E of this Act and section \n        351(m) of the Public Health Service Act, as applicable, with \n        respect to the drug.\n    ``(c) Limitations.--Any extension described in subsection (b)(1) \nshall not apply if the drug designated under subsection (a)(1) has \npreviously received an extension by operation of subsection (b)(1).\n    ``(d) Definition.--In this section, the term `rare disease or \ncondition' has the meaning given to such term in section 526(a)(2).''.\n    (b) Application.--Section 505G of the Federal Food, Drug, and \nCosmetic Act, as added by subsection (a), applies only with respect to \na drug for which an application or supplemental application described \nin subsection (a)(1)(B)(i) of such section 505G is first approved under \nsection 505(c) of such Act (21 U.S.C. 355(c)) or section 351(a) of the \nPublic Health Service Act (42 U.S.C. 262(a)) on or after the date of \nthe enactment of this Act.\n    (c) Conforming Amendments.--\n            (1) Relation to pediatric exclusivity for drugs.--Section \n        505A of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. \n        355a) is amended--\n                    (A) in subsection (b), by adding at the end the \n                following:\n            ``(3) Relation to exclusivity for a drug approved for a new \n        indication for a rare disease or condition.--Notwithstanding \n        the references in paragraph (1) to the lengths of the \n        exclusivity periods after application of pediatric exclusivity, \n        the 6-month extensions described in paragraph (1) shall be in \n        addition to any extensions under section 505G.''; and\n                    (B) in subsection (c), by adding at the end the \n                following:\n            ``(3) Relation to exclusivity for a drug approved for a new \n        indication for a rare disease or condition.--Notwithstanding \n        the references in paragraph (1) to the lengths of the \n        exclusivity periods after application of pediatric exclusivity, \n        the 6-month extensions described in paragraph (1) shall be in \n        addition to any extensions under section 505G.''.\n            (2) Relation to exclusivity for new qualified infectious \n        disease products that are drugs.--Subsection (b) of section \n        505E of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. \n        355f) is amended--\n                    (A) by amending the subsection heading to read as \n                follows: ``Relation to Pediatric Exclusivity and \n                Exclusivity for a Drug Approved for a New Indication \n                for a Rare Disease or Condition.--''; and\n                    (B) by striking ``any extension of the period under \n                section 505A'' and inserting ``any extension of the \n                periods under sections 505A and 505G, as applicable,''.\n            (3) Relation to pediatric exclusivity for biological \n        products.--Section 351(m) of the Public Health Service Act (42 \n        U.S.C. 262(m)) is amended by adding at the end the following:\n            ``(5) Relation to exclusivity for a biological product \n        approved for a new indication for a rare disease or \n        condition.--Notwithstanding the references in paragraphs \n        (2)(A), (2)(B), (3)(A), and (3)(B) to the lengths of the \n        exclusivity periods after application of pediatric exclusivity, \n        the 6-month extensions described in such paragraphs shall be in \n        addition to any extensions under section 505G.''.\n\nSEC. 3. ORPHAN DRUGS.\n\n    (a) In General.--Section 527 of the Federal Food, Drug, and \nCosmetic Act (21 U.S.C. 360cc) is amended--\n            (1) in subsection (a), in the matter following paragraph \n        (2), by striking ``such drug for such disease or condition'' \n        and inserting ``the same drug for the same disease or \n        condition'';\n            (2) in subsection (b)--\n                    (A) in the matter preceding paragraph (1), by \n                striking ``If an application'' and all that follows \n                through ``such license if'' and inserting ``During the \n                7-year period described in subsection (a) for an \n                approved application under section 505 or license under \n                section 351 of the Public Health Service Act, the \n                Secretary may approve an application or issue a license \n                for a drug that is otherwise the same, as determined by \n                the Secretary, as the already approved drug for the \n                same rare disease or condition if'';\n                    (B) in paragraph (1), by striking ``notice'' and \n                all that follows through ``assure'' and inserting ``of \n                exclusive approval or licensure notice and opportunity \n                for the submission of views, that during such period \n                the holder of the exclusive approval or licensure \n                cannot ensure''; and\n                    (C) in paragraph (2), by striking ``such holder \n                provides'' and inserting ``the holder provides''; and\n            (3) by adding at the end the following:\n    ``(c) Condition of Clinical Superiority.--\n            ``(1) In general.--If a sponsor of a drug that is \n        designated under section 526 and is otherwise the same, as \n        determined by the Secretary, as an already approved or licensed \n        drug is seeking exclusive approval or exclusive licensure \n        described in subsection (a) for the same rare disease or \n        condition as the already approved drug, the Secretary shall \n        require such sponsor, as a condition of such exclusive approval \n        or licensure, to demonstrate that such drug is clinically \n        superior to any already approved or licensed drug that is the \n        same drug.\n            ``(2) Definition.--For purposes of paragraph (1), the term \n        `clinically superior' with respect to a drug means that the \n        drug provides a significant therapeutic advantage over and \n        above an already approved or licensed drug in terms of greater \n        efficacy, greater safety, or by providing a major contribution \n        to patient care.\n    ``(d) Regulations.--The Secretary may promulgate regulations for \nthe implementation of subsection (c). Beginning on the date of \nenactment of the Orphan Products Extension Now Accelerating Cures and \nTreatments Act of 2017, until such time as the Secretary promulgates \nregulations in accordance with this subsection, the Secretary may apply \nany definitions set forth in regulations that were promulgated prior to \nsuch date of enactment, to the extent such definitions are not \ninconsistent with the terms of this section, as amended by such Act.\n    ``(e) Demonstration of Clinical Superiority Standard.--To assist \nsponsors in demonstrating clinical superiority as described in \nsubsection (c), the Secretary--\n            ``(1) upon the designation of any drug under section 526, \n        shall notify the sponsor of such drug in writing of the basis \n        for the designation, including, as applicable, any plausible \n        hypothesis offered by the sponsor and relied upon by the \n        Secretary that the drug is clinically superior to a previously \n        approved drug; and\n            ``(2) upon granting exclusive approval or licensure under \n        subsection (a) on the basis of a demonstration of clinical \n        superiority as described in subsection (c), shall publish a \n        summary of the clinical superiority findings.''.\n    (b) Rule of Construction.--Nothing in the amendments made by \nsubsection (a) shall affect any determination under sections 526 and \n527 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bb, \n360cc) made prior to the date of enactment of the Orphan Products \nExtension Now Accelerating Cures and Treatments Act of 2017.\n\nSEC. 4. PEDIATRIC INFORMATION ADDED TO LABELING.\n\n    Section 505A(o) of the Federal Food, Drug, and Cosmetic Act (21 \nU.S.C. 355a(o)) is amended--\n            (1) in the subsection heading, by striking ``Under Section \n        505(j)'';\n            (2) in paragraph (1)--\n                    (A) by striking ``under section 505(j)'' and \n                inserting ``under subsection (b)(2) or (j) of section \n                505''; and\n                    (B) by striking ``or by exclusivity under clause \n                (iii) or (iv) of section 505(j)(5)(F)'' and inserting \n                ``, or by exclusivity under clause (iii) or (iv) of \n                section 505(j)(5)(F), clauses (iii) and (iv) of section \n                505(c)(3)(E), or section 527(a), or by an extension of \n                such exclusivity under this section or section 505E'';\n            (3) in paragraph (2), in the matter preceding subparagraph \n        (A)--\n                    (A) by inserting ``clauses (iii) and (iv) of \n                section 505(c)(3)(E), or section 527,'' after ``section \n                505(j)(5)(F),''; and\n                    (B) by striking ``drug approved under section \n                505(j)'' and inserting ``drug approved pursuant to an \n                application submitted under subsection (b)(2) or (j) of \n                section 505''; and\n            (4) by amending paragraph (3) to read as follows:\n            ``(3) Preservation of pediatric exclusivity and other \n        provisions.--This subsection does not affect--\n                    ``(A) the availability or scope of exclusivity \n                under--\n                            ``(i) this section;\n                            ``(ii) section 505 for pediatric \n                        formulations; or\n                            ``(iii) section 527;\n                    ``(B) the question of the eligibility for approval \n                of any application under subsection (b)(2) or (j) of \n                section 505 that omits any other conditions of approval \n                entitled to exclusivity under--\n                            ``(i) clause (iii) or (iv) of section \n                        505(j)(5)(F);\n                            ``(ii) clause (iii) or (iv) of section \n                        505(c)(3)(E); or\n                            ``(iii) section 527; or\n                    ``(C) except as expressly provided in paragraphs \n                (1) and (2), the operation of section 505 or section \n                527.''."
}